Sol Gel Financials
SLGL Stock | USD 1.05 0.06 5.41% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.7 | 8.19 |
|
|
The essential information of the day-to-day investment outlook for Sol Gel includes many different criteria found on its balance sheet. An individual investor should monitor Sol Gel's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sol Gel.
Net Income |
|
Sol | Select Account or Indicator |
Sol Gel Stock Summary
Sol Gel competes with Pmv Pharmaceuticals, MediciNova, Pharvaris, PepGen, and Aerovate Therapeutics. Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Sol-Gel Technologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 53 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | IL0011417206 |
CUSIP | M8694L103 |
Location | Israel |
Business Address | 7 Golda Meir |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.sol-gel.com |
Phone | 972 8 931 3433 |
Currency | USD - US Dollar |
Sol Gel Key Financial Ratios
Return On Equity | -0.36 | ||||
Profit Margin | (2.27) % | ||||
Operating Margin | 0.30 % | ||||
Price To Sales | 4.44 X | ||||
Revenue | 1.55 M |
Sol Gel Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 59.2M | 69.2M | 46.6M | 45.3M | 52.1M | 42.7M | |
Other Liab | 958K | 1.0M | 1.1M | 1.0M | 1.2M | 959.7K | |
Net Tangible Assets | 52.5M | 50.8M | 55.6M | 42.2M | 48.5M | 51.0M | |
Retained Earnings | (181.4M) | (178.1M) | (193.1M) | (220.3M) | (198.3M) | (208.2M) | |
Accounts Payable | 1.2M | 766K | 251K | 154K | 177.1K | 168.2K | |
Cash | 7.1M | 20.1M | 12.4M | 7.5M | 8.6M | 8.8M | |
Other Assets | 2.0M | 9.5M | 2.0M | 1.0 | 1.15 | 1.09 | |
Total Liab | 8.3M | 13.6M | 4.4M | 6.6M | 6.0M | 5.7M | |
Total Current Assets | 53.4M | 57.1M | 43.1M | 41.2M | 47.3M | 37.7M | |
Short Term Debt | 1.3M | 1.6M | 1.4M | 447K | 402.3K | 382.2K | |
Common Stock | 561K | 635K | 638K | 774K | 890.1K | 450.3K | |
Other Current Liab | 3.4M | 9.4M | 1.6M | 3.9M | 4.5M | 3.8M | |
Net Debt | (5.2M) | (18.5M) | (11.7M) | (5.9M) | (5.3M) | (5.0M) | |
Other Current Assets | 1.1M | 800K | 1.5M | 2.8M | 3.2M | 1.9M | |
Net Invested Capital | 50.8M | 55.6M | 42.2M | 38.6M | 44.4M | 49.7M | |
Net Working Capital | 47.4M | 45.4M | 39.7M | 36.6M | 42.1M | 35.0M | |
Capital Stock | 561K | 635K | 638K | 774K | 890.1K | 690.4K | |
Net Receivables | 2.2M | 13.1M | 7.9M | 377K | 339.3K | 322.3K |
Sol Gel Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Investments | (2.7M) | 19.9M | 1.7M | (9.7M) | (11.2M) | (11.8M) | |
Change In Cash | (1.5M) | 13.0M | (7.6M) | (5.7M) | (5.2M) | (4.9M) | |
Depreciation | 946K | 880K | 562K | 342K | 393.3K | 630.7K | |
Capital Expenditures | 449K | 143K | 171K | 134K | 120.6K | 114.6K | |
Net Income | (29.3M) | 3.2M | (14.9M) | (27.2M) | (24.5M) | (25.7M) | |
End Period Cash Flow | 8.3M | 21.2M | 13.6M | 7.9M | 9.0M | 9.3M | |
Change To Netincome | 2.7M | 1.5M | 628K | 1.3M | 1.2M | 2.1M | |
Free Cash Flow | (25.7M) | (7.8M) | (9.7M) | (17.9M) | (20.5M) | (21.6M) | |
Other Non Cash Items | 12K | 55K | (14K) | 1.0M | 928.8K | 687.9K |
Sol Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sol Gel's current stock value. Our valuation model uses many indicators to compare Sol Gel value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sol Gel competition to find correlations between indicators driving Sol Gel's intrinsic value. More Info.Sol Gel Technologies is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Sol Gel's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sol Gel by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Sol Gel Technologies Systematic Risk
Sol Gel's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sol Gel volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Sol Gel Technologies correlated with the market. If Beta is less than 0 Sol Gel generally moves in the opposite direction as compared to the market. If Sol Gel Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sol Gel Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sol Gel is generally in the same direction as the market. If Beta > 1 Sol Gel moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Sol Gel Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sol Gel's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sol Gel growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Sol Gel January 12, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sol Gel help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sol Gel Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sol Gel Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Sol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sol Gel's daily price indicators and compare them against related drivers.
Downside Deviation | 10.74 | |||
Information Ratio | 0.0927 | |||
Maximum Drawdown | 324.33 | |||
Value At Risk | (12.90) | |||
Potential Upside | 10.42 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sol Gel Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sol Gel. If investors know Sol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sol Gel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share | Quarterly Revenue Growth 8.146 | Return On Assets | Return On Equity |
The market value of Sol Gel Technologies is measured differently than its book value, which is the value of Sol that is recorded on the company's balance sheet. Investors also form their own opinion of Sol Gel's value that differs from its market value or its book value, called intrinsic value, which is Sol Gel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sol Gel's market value can be influenced by many factors that don't directly affect Sol Gel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sol Gel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sol Gel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sol Gel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.